Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027947 (neutropenia)
 17,527 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-three patients with histologically proven bronchogenic carcinoma of the lung were treated with regimen consisting of 3 intravenous doses of 0.4 mg/kg of MTX and intravenous infusion of 30-50 mg/kg body weight of CPM. Interval between 1st and 2nd dose of MTX, which served as synchronizing agent in phase G1/S, was 12 hrs, and interval between 2nd and 3rd dose -- 6 hrs. Infusion of CPM, which was considered to be a preferably S-phase killer was started simultaneously with administration of 3rd dose of MTX. Such courses were repeated every 21-30 days. Objective responses were noted in 10 of 19 adequately treated patients. MTX-CPM favourably influenced survival of the responders. The therapy was, however associated with a number of adverse reactions, from which neutropenia and complicating bacterial infections were particularly dangerous.
 ...
PMID:Combination of ametopterine (MTX) and cyclophosphamide (CPM) based on the principle of partial synchronization of cell proliferation in lung cancer. Phase II study. 99 56

Ten cases of newly diagnosed pediatric B cell non-Hodgkin's lymphoma or acute lymphoblastic leukemia (B-NHL, stage I & II 6 cases, stage III & IV 2 cases/ALL 2 cases) experienced during the last 7 years (1987-1994) were treated by BLK88 protocol, which consisted of HD-CPM (1,200 mg/m2), and HD-MTX (1,000 mg/m2) with VCR, ADR, and/or AraC combination, and CNS prophylaxis by triple intrathecal injection. The therapy duration was 24 weeks for B-NHL (36 weeks for B-ALL). The results showed that while one of the six cases in stage I & II relapsed, and other 4 cases of stage III & IV B-NHL/ALL remained in complete remission. On the other hand, all of the four cases in stage III & IV in historical controls had relapsed. Neutropenia and liver dysfunction were observed during therapy, but they were tolerable. We conclude that BLK88 is a very useful protocol for B-NHL/ALL in childhood.
 ...
PMID:[Chemotherapy for B lymphoid malignancy in childhood--results in BLK88 protocol]. 884 99